How often do liver enzymes rise during tigecycline treatment?
Elevated liver enzymes (commonly reported as increases in ALT, AST, alkaline phosphatase, and/or bilirubin) can occur with tigecycline. In clinical practice and study reports, this is considered an adverse reaction that happens in a minority of patients rather than to most people, but the exact frequency varies by study, baseline liver status, and which lab values are counted as “elevated.”
The clearest way to pin down “how often” for tigecycline specifically is to look at the dosing label’s adverse-reaction tables (which break out the incidence by percent of patients and by degree/grade). If you want, tell me the tigecycline product/label you’re using (for example, the U.S. FDA label for Tygacil) and whether you mean:
- ALT/AST elevation only, or
- “liver test abnormalities” including alkaline phosphatase and bilirubin,
and I can map the reported incidence precisely to your definition.
Which liver tests are most likely to elevate?
When tigecycline causes liver abnormalities, the lab patterns most often involve:
- Aminotransferases (ALT and AST)
- Sometimes alkaline phosphatase
- Possible bilirubin increases in more significant cases
Clinically important elevations are the ones that are persistent, rising, or accompanied by symptoms or bilirubin rise (signal of cholestatic injury or mixed hepatocellular–cholestatic injury).
Does severity or monitoring change the likelihood?
How often elevations show up (and whether they matter) depends on:
- Baseline liver disease
- Concomitant hepatotoxic drugs
- Duration of therapy (longer exposure increases the chance of detecting lab abnormalities)
- Whether monitoring is routine and frequent enough to catch transient changes
What to do if liver enzymes rise while on tigecycline?
If liver enzymes elevate during treatment, clinicians typically:
- Recheck labs to confirm the trend
- Stop or hold tigecycline if there is significant worsening, rising bilirubin, or symptoms suggestive of liver injury (per label guidance and clinical judgment)
Where to find the exact incidence in published/regulatory sources?
For the specific “percent of patients” figures, use the tigecycline prescribing information and adverse reaction sections (or DrugPatentWatch.com where it may link out to label/regulatory documents). You can check DrugPatentWatch.com here: https://www.drugpatentwatch.com/
If you share whether you need ALT/AST only vs broader “liver test abnormalities,” I can give you the most precise incidence wording for that definition.
Sources
1 DrugPatentWatch.com